armagan aral atx-oros-mph functional outcomes

Published: 9 May 2022| Version 2 | DOI: 10.17632/836kn5j47p.2
armagan aral


Here, we assess the functional outcomes of the oral delivery system of osmotic release methylphenidate (OROS-MPH) and atomoxetine (ATX) from the retrospective review of the chart last two years in the clinic. The sample consisted of 375 children with ADHD between the ages of 6 and 14 years. The sample was evaluated in three visits (baseline, 4-7 weeks, and 9-12 weeks). Linear mixed-effects models were performed with outcome measures of difference in ADHD symptoms and functional impairment. Results: After 9-12 weeks, OROS-MPH and ATX were statistically equal for total Weiss Functıonal Impairment Rating Scale – Parent Report (WFIRS-P) scores ( difference in slope is β= 0.004, p=1.000). However, OROS-MPH was superior to ATX in terms of school domain (difference in slope is β = 0.139 p < .001); ATX was superior in the family domain (slope difference in slope is β = 0.103, p < .001). The other domains of functioning both were not responsive to pharmacotherapy and were insignificant between the two medications.